Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (22271)	6/15/1998 5:09:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 32384

I agree. I've been reading about Ligand from time to time for a couple of years now. (I stop reading for long periods because of the tedious postings that go on for long stretches) My take on the company is that it may be a company even worse than our old IDTI: long on promise, short on delivery. So far, Richard Harmon seems more than justified in his opinion about LGND's performance to date. Personally, I like to invest in biotech companies that are focused on their end goals - Ligand seems like a distracted company. I like companies that stay lean, stick with their program doggedly, bring a product to market and repeat the cycle - no acquisitions, no expensive big picture stuff, until you get something right and prove out your concept. The pipeline may or may not be great. And citing analysts who recommend the stock is probably no better than citing our own opinions - nobody really knows what data will emerge from the clinic. So far, there are only promises holding this stock afloat.